3 Humongous Health-Care Stocks This Week

Intercept Pharmaceuticals, Neurocrine Biosciences, and Epizyme achieve stunning gains in a great week for health-care investors.

Jan 11, 2014 at 8:10AM

What a week for health-care investors! At least 17 health-care stocks experienced gains of more than 20% over the past few days. But three of those went up a lot more than just 20%. Here are the three most humongous health-care stocks of the week.

Up, up, and away
On Jan. 3, tiny Intercept Pharmaceuticals (NASDAQ:ICPT) traded just over $69 per share. By end of day this past Thursday, the stock was up nearly 300%. By the end of the week, Intercept had gained a staggering 545%. That's right -- this stock was a six-bagger in just seven days.

Where did all of this exuberance come from? A phase 2 study of Intercept's obeticholic acid targeting treatment of nonalcoholic steathohepatitis, or NASH, produced results so positive that the data safety monitoring board recommended that the trial be stopped early. The unexpected news led to multiple investment firms hiking price targets for Intercept -- with the stock literally skyrocketing in response.

Investors' excitement is directly linked to the current situation for NASH. More than 6 million Americans suffer from the liver disease that can ultimately lead to cirrhosis -- even though patients drink little or no alcohol. There are currently no approved drugs for the disease. Should Intercept ultimately gain approval for obeticholic acid, that's a big untapped market.    

Picking up where it left off
Back in September, Neurocrine Biosciences (NASDAQ:NBIX) hit a rough spell. Shares plummeted after disappointing results from a phase 2b study of tardive dyskinesia drug NBI-98854, which ultimately cut Neurocrine's market cap in half. This week, though, shares came roaring back with Neurocrine gaining over 98%.

The catalyst was the same thing that led to the stock collapse a few months ago -- a phase 2b study for NBI-98854 in treating tardive dyskinesia. This time around, though, Neurocrine had its ducks in a row on reducing the potential for the placebo effect to call the efficacy of NBI-98854 into question. A better study design led to better results.

While the latest news certainly got Neurocrine back on track, the company still must move forward with a late-stage study. It remains to be seen how NBI-98854 will fare in a larger trial, but at least Neurocrine knows now how to avoid the mistakes from earlier in 2013.

Proof positive
Clinical-stage biopharmaceutical firm Epizyme (NASDAQ:EPZM) announced good results from a phase 1 study. The market liked what it heard -- shares soared almost 97% for the week.

Normally, an early stage study wouldn't make that big of a difference. But the results for Epizyme's acute leukemia drug EPZ-5676 earned the company a $25 million proof-of-concept milestone payment from partner Celgene (NASDAQ:CELG). That puts Epizyme in a considerably better cash position than previously forecasted.

Epizyme's positive results could conceivably attract even more interest from Celgene. The company has made several acquisitions in the past that have helped make it one of the best big biotechs around. One of the keys for Celgene's continued success is in making more smart investments. Epizyme just might fit that bill.

Going even higher
It probably sounds crazy to some, but Intercept just might have the most room to run higher out of all three of this week's humongous health-care stocks. Yes, there will likely be a lot of volatility in the stock. And there are plenty of risks. However, the market potential assuming Intercept ultimately wins approval for obeticholic acid is big enough to support a higher valuation even after this week's massive gains.

Having said that, I do like Epizyme's potential. Celgene appears to have chosen wisely in partnering with the smaller company. Neurocrine, likewise, could have a bright future if phase 3 testing of its tardive dyskinesia drug goes well. Any of these three stocks could continue to produce wins for investors. Just don't expect a repeat of this week's amazing runs. 

1 potentially humongous stock for the new year
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Keith Speights owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers